Checking in on U.S. knee replacement, smaller form factor technology and the outlook for the trauma segment.
The Numbers
Selected comments from the leaders of top orthopedic companies as they reported first quarter 2026 earnings.
Highlights from the brand new 2026 edition include the health of end markets, dynamics at play in the trauma segment, and the tantalizing promise of orthobiologics.
Orthoflash®
MISHA is shown to be effective for knee OA patients who failed non-surgical treatments, but are not indicated or are unwilling to get a knee replacement.
June 23, 2026
,
The project is on track to reach the next milestone toward CE Mark approval of HyProtect-coated revision implants.
June 23, 2026
,
FDA approved an IDE application for a pivotal clinical trial of SOLA-2 Alternating Magnetic Field System in patients with periprosthetic joint infections.
June 23, 2026
,
This marks the company’s entry into the U.S. bone graft substitute market, and represents the first clearance of a device based on its proprietary JAZBI biomaterial.
June 19, 2026
,
HyperPlate fixation technology advances the SpeedPlate implant platform by incorporating FastPitch locking screws into the titanium compression implants.
June 18, 2026
,
Competitive Landscape
ORTHOWORLD Experts talk you through market forecasts, company sales and key trends.
Industry Voices
